DEALS
Zhong Lun Represents Adicon to Acquire Crown Biosciences
Zhong Lun Represents Adicon to Acquire Crown Biosciences
Zhong Lun represented Adicon Holdings Limited (9860.HK) (“Adicon”), a portfolio company of The Carlyle Group, to acquire Crown Biosciences, a global CRO, from JSR Life Science, LLC. The transaction was announced on November 13, 2025 and, subject to customary closing conditions, is expected to close in 2026.
This transaction involved multiple jurisdictions. The Zhong Lun team acted as lead M&A counsel for Adicon, responsible for negotiations and documentation, and coordinating and managing various local regulatory and due diligence legal advisors.
In connection with the transaction, the Zhong Lun team was led by partners Gary Li and Boxin Wang, with support from non-equity partner Stacey Shen and associate Kristen Huang. Zhong Lun also acted as PRC counsel for the transaction. The PRC legal team was led by partners Luke Zhang and Frank Jiang.
Professionals
-
-
Stacey Shen
Non-equity Partner
Hong KongPractices： Private Equity & Investment Funds -
Stacey Shen
Non-equity Partner
Hong Kong
-
-
-
Luke ZHANG
Equity Partner
ShanghaiPractices： Private Equity & Investment Funds,Cross-border Investment/M&A,Hong Kong & Overseas Capital MarketsIndustries： Telecom & Information,Intelligence Technology & Application,Pharmaceuticals & Life Sciences,Healthcare,Education & Training,Media, Sports & Entertainment,Financial Innovation & Fintech -
Luke ZHANG
Equity Partner
Shanghai
-
